Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Veziris, Nicolas ^a,b,c   Ibrahim, Murad ^a,b,c,d   Lounis, Nacer ^e   Andries, Koen ^e   Jarlier, Vincent ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔpital Robert Debré   (France)

^d AL QUDS UNIVERSITY   (Palestine)

^e Tibotec BVBA ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; AMIKACIN; ETHIONAMIDE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; 1 (6 BROMO 2 METHOXY QUINOLIN 3 YL) 4 DIMETHYLAMINO 2 (3 FLUOROPHENYL) 1 PHENYL BUTAN 2 OL; 1-(6-BROMO-2-METHOXY-QUINOLIN-3-YL)-4-DIMETHYLAMINO-2-(3-FLUOROPHENYL)-1-PHENYL-BUTAN-2-OL; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RELAPSE; SURVIVAL RATE; SWISS WEBSTER MOUSE; TREATMENT DURATION; ANIMAL; BACTERIAL COUNT; DRUG EFFECT; INSTRUMENT STERILIZATION; LUNG; MICROBIOLOGY; ORGAN SIZE; PATHOLOGY; RECURRENT DISEASE; SPLEEN; SURVIVAL; TUBERCULOSIS;

MURINAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; LUNG; MICE; MYCOBACTERIUM TUBERCULOSIS; ORGAN SIZE; QUINOLINES; RECURRENCE; SPLEEN; STERILIZATION; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 79952422865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017556     Document Type: Article

References (34)

1. Dye C, (2006) Global epidemiology of tuberculosis. Lancet 367: 938-940.
2. Williams B, Maher D, (2007) Tuberculosis fueled by HIV: putting out the flames. Am J Respir Crit Care Med 175: 6-8.
3. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344: 1294-1303.
4. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, et al. (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194: 479-485.
5. World Health Organization (2006) Guidelines for the programmatic management of drug-resistant tuberculosis Geneva WHO.
6. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N, (2009) Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 180: 553-557.
7. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
8. Veziris N, Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, (2007) R207910 containing regimens display high sterilizing activity in the murine model of tuberculosis; Chicago, USA.
9. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, et al. (2006) Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50: 3543-3547.
10. Grosset J, Truffot-Pernot C, Lacroix C, Ji B, (1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36: 548-551.
11. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, et al. (2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421-426.
12. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, et al. (2004) Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131-1134.
13. Truffot-Pernot C, Ji B, Grosset J, (1991) Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72: 57-64.
14. Lecoeur HF, Truffot-Pernot C, Grosset JH, (1989) Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140: 1189-1193.
15. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N, (2003) Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 47: 3117-3122.
16. Grosset J, Ji B, (1998) Experimental chemotherapy of mycobacterial diseases. In: Gandharam PR, Jenkins P, editors. Mycobacteria New-York Marcel Dekker pp. 51-97.
17. McCune RM Jr, McDermott W, Tompsett R, (1956) The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104: 763-802.
18. McCune RM Jr, Tompsett R, (1956) Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 104: 737-762.
19. McMurray DN, (2000) A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin Infect Dis 30 (Suppl 3): S210-212.
20. Grosset J, (2003) Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 47: 833-836.
21. Lounis N, Ji B, Truffot-Pernot C, Grosset J, (1997) Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 41: 607-610.
22. Grumbach F, (1965) Etudes chimiothérapiques sur la tuberculose avancée de la souris Bâle/New-York Karger pp. 31-96.
23. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, et al. (2010) Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 54: 4765-4771.
24. Lubasch A, Keller I, Borner K, Koeppe P, Lode H, (2000) Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 44: 2600-2603.
25. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, et al. (2005) Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med 172: 1457-1462.
26. Lenaerts AJ, Chapman PL, Orme IM, (2004) Statistical limitations to the Cornell model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb) 84: 361-364.
27. Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH, (2007) Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents Chemother 51: 403; author reply 403-404.
28. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, et al. (2010) Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684-692.
29. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
30. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, et al. (2001) Occurrence of serious adverse effects in patients receiving community- based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 5: 648-655.
31. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, et al. (2001) The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345: 170-174.
32. Andries K, Gevers T, Lounis N, (2010) Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 54: 4540-4544.
33. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, et al. (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 51: 1011-1015.
34. Mc Neeley DF, Diacon AH, Pym A, Grobusch M, Gotuzzo E, et al. TMC207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial 2010; Berlin.